$SAVA September 3rd 2021 Remi Barbier said, "I truly believe Cassava Sciences is one clinical program away from greatness.

MOST IMPORTANTLY, THE RESULTS MUST HAVE BEEN GOOD AND PROMISING at each snapshot that leads Remi to use the word "Thrilled" in Dec 6 PR.

$SAVA Remi is "thrilled" with the progress to date.

$SAVA Per press release dec 6 2022, Remi stated administration of drug for OL study completed and he is "THRILLED" with the clinical development, or what he see to this date.

$SAVA The stock should continually "Gravitate" upwards toward the 20 , 50 , 200 where price should have been all along , on its way to new highs.

$SAVA "Cassava has such a great Alzheimers drug" is what you will start to believe if you watxhbthe YouTube pumper's endless videos on how great cassava drug is.

$BIVI Biovie Pharmaceuticals $BIVI passes Zacks Equity Research's strict "Recent Price Strength screen", and comes out with glowing colors--and a prediction of further momentum for the stock in near term.

$SAVA We had what I would call a very "healthy" climb.

Missling is being "patient" taking months longer than any other company to analyze and release trial data (and then not actually releasing the full data set), so he's awesome.

Abrahams sees ultimate approval as "very likely" and a favorable setup in Biogen shares.

$AVXL George Perry stated, the Anavex drug is "revolutionary", as is uniquely good, no other drug has EVER increased cognition EVER.

IMO, with their "rapid" label and test showing sustained improvement in cognition and daily living, it will be hard not to try Auvelity if you suffer from MDD.

Value is what you get. "Revolutionary."

The results are incredible and 50mg study with no side effects is spectacular."

The information points clearly this is much better than "Aduhelm" or Lecanemab.

$TGTX next few weeks will be a good buying opportunity for "risk on" assets imo.

$TGTX "4 Stories of Living with Multiple Sclerosis" Briumvi, the best and most affordable, 1HR infusion, no black box label warning, and no warning or report of causing breast cancer.

The analyst comments "TGTX stock is up >15% (versus +4% for XBI) driven by: 1) positive comments on pricing: we think list price is rational with some discount vs. Ocrevus to lower cost burden and get broad access,

The analyst comments "TGTX stock is up >15% (versus +4% for XBI) driven by: 1) positive comments on pricing: we think list price is rational with some discount vs. Ocrevus to lower cost burden and get broad access,

Check it out below.""" 👇 Highly recommend everyone to follow them 💪 https://amazing-stocks-us.stockmarketus.net/